Epinor Tablets

Composition

Each film coated tablet contains: 

Norfloxacin ………………………………………………………………. 400 mg

Inactive ingredients: 

Lactose DC anhydrous, croscarmellose sodium, starch 1500, magnesium stearate, sodium lauryl sulphate, talc purified, colloidal silicon dioxide, hydroxypropyl methylcellulose, hydroxypropyl cellulose, titanium dioxide, iron oxide red, polysorbate 80, dibutyl phthalate.

Therapeutic Indications

EPINOR is indicated for the treatment of the following bacterial infections caused by pathogens susceptible to norfloxacin: upper and lower complicated and uncomplicated, acute and chronic urinary tract infections, including cystitis and pyelitis, and also for the treatment of chronic prostatitis.

Consideration should be given to official local guidance e.g. national recommendations regarding the appropriate use and prescription of antibacterial agents.

Susceptibility of the causative organism to the treatment should be tested (if possible), although therapy may be initiated before the results are available.

In case of suspected failure of therapy, microbiological investigation for possible bacterial resistance should be undertaken.

Fluoroquinolones should be reserved for use in patients who have no other treatment options for acute bacterial sinusitis, (ABS), acute bacterial exacerbation of chronic bronchitis (ABECB), and uncomplicated urinary tract infections (UTI).

Fluoroquinolones should not be used in the following indications:

To treat infections that might get better without treatment or are not severe (such as throat infections).

To treat non-bacterial infections, e.g. non-bacterial (chronic) prostatitis.

For preventing traveller’s diarrhoea or recurring lower urinary tract infections (urine infections that do not extend beyond the bladder).

To treat mild or moderate bacterial infections unless other antibacterial medicines commonly recommended for these infections cannot be used.